Medical Properties Trust, Inc. MPT
3.57
(0.03)
(0.83%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 0.0×
Follow MPT
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.26 | 3.09 | 2.77 | 2.71 | |
P/FCF ratio |
11.73 | 11.07 | 10.30 | 10.68 | |
P/Operating CF |
164.11 | 18.77 | (194.08) | 44.24 | |
P/B ratio |
0.65 | 0.65 | 0.61 | 0.61 | |
Price to Tangible BV |
0.65 | 0.65 | 0.61 | 0.61 | |
EV/Sales |
13.14 | 12.51 | 12.00 | 11.84 | |
EV/EBITDA |
39.10 | 37.02 | 34.30 | 33.81 | |
EV/Operating CF |
83.23 | 52.70 | 55.55 | 53.22 | |
EV/FCF |
47.22 | 44.82 | 44.68 | 46.65 | |
Quick Ratio |
2.68 | 2.63 | 3.11 | 3.12 | |
Current Ratio |
2.68 | 2.63 | 3.11 | 3.12 | |
Net Debt/EBITDA |
136.09 | 80.86 | 105.93 | 104.84 | |
Debt/Assets |
64.43% | 64.64% | 65.45% | 65.81% | |
Debt/Equity |
2.06 | 2.10 | 2.13 | 2.16 | |
Asset Turnover |
0.06 | 0.07 | 0.07 | 0.07 | |
Operating CF/Net income |
(0.24) | 9.25 | (0.43) | (24.06) | |
Capex/Depreciation |
0.38 | 0.06 | 0.07 | (0.09) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.89% | 9.09% | 12.78% | 13.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.20% | (1.89%) | 0.23% | 1.87% | |
Graham Net Nets |
(2.95) | (2.98) | (3.21) | (3.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.27%) | (9.20%) | (4.54%) | (1.16%) | |
Free Cash Flow Yield |
8.52% | 9.03% | 9.71% | 9.37% | |
Revenue per Share |
0.40 | 0.45 | 0.42 | 0.43 | |
Operating CF per Share |
0.03 | 0.27 | (0.02) | 0.10 | |
Capex per Share |
0.05 | 0.01 | 0.01 | (0.01) | |
Free Cash Flow per Share |
0.08 | 0.27 | (0.01) | 0.09 | |
Cash per Share |
0.66 | 0.90 | 0.71 | 0.66 | |
Shareholders Equity per Share |
7.75 | 7.67 | 7.61 | 7.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.75 | 7.67 | 7.61 | 7.53 | |
Free Cash Flow |
47.49 | 164.40 | (8.48) | 55.37 | |
Working Capital |
797.53 | 892.42 | 913.89 | 912.33 | |
Capital Expenditures |
28.92 | 4.33 | 5.78 | (7.07) | |
Net Current Asset Value |
(8,989.36) | (8,953.01) | (8,869.86) | (8,905.43) | |
EV/EBIT |
616.05 | 413.47 | 287.16 | 277.32 | |
Capex to Sales |
(0.12) | (0.02) | (0.02) | 0.03 | |
Net Profit Margin |
(32.73%) | 6.40% | 13.02% | (1.00%) | |
Price to Operating Income |
153.05 | 102.15 | 66.20 | 63.47 | |
| Other line items | |||||
Average Receivables |
798.89 | 818.89 | 852.17 | 900.17 | |
Average Payables |
447.14 | 501.66 | 442.22 | 462.43 | |
Average Assets |
15,080.18 | 14,648.19 | 14,808.28 | 14,949.09 | |
Average Common Equity |
5,051.23 | 4,720.52 | 4,653.92 | 4,666.86 |
Columns are period end dates